CROFAB -Effective Antivenom, Utilizing Venom
CroFab® is the only antivenom derived exclusively from US snakes to treat all North American pit viper envenomations in adult and pediatric patients.1,2 98% of venomous snakebites in the United States are from the North American pit viper. Approved in 2000, CroFab® was designed to reduce the high incidence of hypersensitivity that occurred with previous antivenom therapy, and to provide a geographically relevant antivenom. In the years since, CroFab® has become the antivenom that healthcare professionals rely on for the treatment of North American pit viper envenomation.1,4
- Halt local effects, such as edema and ecchymosis, and treat the source of the pain1
- Resolve systemic effects, such as nausea, vomiting, dizziness, or tachycardia1
- Reduce coagulation abnormalities, such as thrombocytopenia, hyperfibrinogenemia, and spontaneous bleeding1,5
*Efficacy determined using the snakebite severity score (SSS), a validated objective tool for the clinical evaluation of North American pit viper snakebite in adults. The total score reflects patient evaluation on 6 dimensions: cardiovascular system, local wound, gastrointestinal system, hematologic symptoms, pulmonary system, and central nervous system. The higher the total score, the more severe the snakebite.1
CroFab® consists of venom-specific Fab fragments of immunoglobulin G (IgG) that work by binding to and neutralizing venom toxins, facilitating their redistribution away from target tissues and their elimination from the body.1
How CroFab® Works
- Venom-specific Fab binds and neutralizes venom toxins1
- Facilitates venom toxin redistribution away from target tissues1
- Facilitates venom toxin elimination from the body1
- Derived exclusively from native US snakes for comprehensive coverage of all US pit viper venoms1
- A safety profile you can count on1
- Included in unified consensus algorithm